ABSTRACT NUMBER: ESOC2026A1026 REAL WORLD ADHERENCE AND OUTCOME OF CYP2C19-GUIDED DUAL ANTIPLATELET THERAPY USING LAB-BASED GENOTYPING IN STROKE MANAGEMENT
Chia Xuan Teoh, Bathma Rajive Bathumalai, Rathika Rajah, Wan Nur Nafisah Wan Yahya, Wan Asraf Wan Zaidi, Mohd Zaki Salleh, Lay Kek Tey, Zhe Law · 2026
Read ABSTRACT NUMBER: ESOC2026A1026 REAL WORLD ADHERENCE AND OUTCOME OF CYP2C19-GUIDED DUAL ANTIPLATELET THERAPY USING LAB-BASED GENOTYPING IN STROKE MANAGEMENT by Chia Xuan Teoh, Bathma Rajive Bathumalai, Rathika Rajah, Wan Nur Nafisah Wan Yahya, Wan Asraf Wan Zaidi, Mohd Zaki Salleh, Lay Kek Tey, Zhe Law (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13146406.txt.
Description
Chia Xuan Teoh and seven co-authors checked in 2026 how well one stroke center followed gene-guided blood thinner choices with slow lab testing. Certain CYP2C19 variants make one drug pair work better than another after minor stroke. Their review covered 167 patients from 2023 and 2024. Tests took a median of two days to return. Final treatment matched the gene result in about two thirds of cases.
Half the patients carried the loss-of-function variant. Repeat stroke within ninety days hit 9.3 percent of carriers versus 2.5 percent of others. Patients whose therapy matched their genotype had far fewer repeat strokes, though the gain on a combined outcome was not firm. The authors conclude that even slow lab genotyping can guide safer choices. Faster testing would likely raise adherence further. The study reports real-world friction in precision prescribing.
Catalog record
| CREATOR | Chia Xuan Teoh, Bathma Rajive Bathumalai, Rathika Rajah, Wan Nur Nafisah Wan Yahya, Wan Asraf Wan Zaidi, Mohd Zaki Salleh, Lay Kek Tey, Zhe Law |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 2 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |